Akoya Biosciences, Inc.

NASDAQ (USD): Akoya Biosciences, Inc. (AKYA)

Last Price

2.41

Today's Change

-0.72 (23.00%)

Day's Change

2.08 - 2.55

Trading Volume

1,259,326

Profile
AKYA

Exchange:  NASDAQ Global Select NASDAQ Global Select

Currency:  USD USD

Sector:  Healthcare - Healthcare Healthcare - Healthcare

Industry: 

CEO:  Mr. Brian McKelligon Mr. Brian McKelligon

Full Time Employees:  330 330

IPO Date:  2021-04-16 2021-04-16

CIK:  0001711933 0001711933

ISIN:  US00974H1041 US00974H1041

CUSIP:  00974H104 00974H104

Beta:  1.35 1.35

Last Dividend:  0.00 0.00

Dcf Diff:  5.02 5.02

Dcf:  -0.03 -0.03

Description

Akoya Biosciences, Inc., a life sciences technology company, provides spatial biology solutions focused on transforming discovery and clinical research in North America, the Asia Pacific, Europe, the Middle East, and Africa. The company offers PhenoCycler instrument, a compact bench-top fluidics system that integrates with a companion microscope to automate image acquisition; and PhenoImager platform that enables researchers to visualize, analyze, quantify, and phenotype cells in situ, in fresh frozen or FFPE tissue sections, and tissue microarrays utilizing an automated and high-throughput workflow. It also provides PhenoCycler and PhenoImager reagents; and biopharma services. In addition, the company offers Proxima, a cloud-based platform to store, analyze, and share spatial data; inForm Tissue, an automated image analysis software package for accurately visualizing and quantifying biomarkers in tissue sections; Phenoptr, which provides functions that consolidate and analyze output tables created by inForm software; and phenoptrReports, a software that generates shareable reports and visualizations based on the phenoptr output in an intuitive front-end GUI. The company was incorporated in 2015 and is headquartered in Marlborough, Massachusetts.

Address

100 Campus Drive,
Marlborough, MA 01752, US

855 896 8401

http://www.akoyabio.com

Discussions
Be the first to like this. Showing 0 of 0 comments

Post a Comment